TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

B Laere, S Oeyen, M Mayrhofer, T Whitington, PJ van Dam, P Van Oyen, C Ghysel, J Ampe, P Ost, W Demey, L Hoekx, D Schrijvers, B Brouwers, W Lybaert, EG Everaert, D De Maeseneer, M Strijbos, A Bols, K Fransis, Nick BeijeInge Kruijff, V Dam, A Brouwer, D Goossens, L Heyrman, GG Van den Eynden, A Rutten, J Del Favero, M Rantalainen, P Rajan, Stefan Sleijfer, A Ullen, J Yachnin, H Gronberg, SJ Van Laere, J Lindberg, LY Dirix

Research output: Contribution to journalArticleAcademicpeer-review

113 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1766-1773
Number of pages8
JournalClinical Cancer Research
Volume25
Issue number6
DOIs
Publication statusPublished - 2019

Research programs

  • EMC MM-03-86-01

Cite this